HSPA5 and familial pancreatic carcinoma: (318) suggested that HSPA5-GPX4 pathway modulation to contribute to chemoresistance in pancreatic cancer cells against gemcitabine, and blocking of HSPA5 or GPX4 gene expression potentially reversing this resistance.